Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Mirati Therapeutics, Inc. (MRTX)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 8.0% | 6.1% | 4.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Gross profit | 92.0% | 93.9% | 95.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 1030.8% | 1372.6% | 1928.3% | | 239.1% | 222.9% | 189.6% | |
| Research and development | 1921.9% | 2791.0% | 4274.9% | 4611.7% | 677.1% | 735.6% | 705.5% | 595.2% |
| General and administrative | | | -869.9% | -274.1% | | | 0.0% | 47.7% |
| EBITDA | -2848.7% | -4053.2% | -6084.4% | -6290.5% | -813.2% | -855.6% | -792.6% | -654.4% |
| Depreciation | 13.9% | 17.9% | 23.6% | 22.0% | 3.1% | 2.9% | 2.5% | 1.9% |
| EBIT | -2862.6% | -4071.1% | -6108.0% | -6312.5% | -816.2% | -858.5% | -795.1% | -656.4% |
| Pre-tax income | -2707.5% | -3898.4% | -5953.4% | -6251.7% | -820.3% | -867.0% | -802.4% | -653.0% |
| Income taxes | 1.9% | 2.7% | 4.1% | 2.2% | 4.2% | 4.5% | 4.6% | 4.5% |
| Net income | -2709.3% | -3901.1% | -5957.4% | -6253.8% | -824.6% | -871.5% | -807.0% | -657.5% |
|